Financials

  • Market Capitalization 22.82 B
  • Employee 2 844
  • Founded 2002
  • CEO Hervé Hoppenot
  • Website www.incyte.com
  • Headquarter Delaware, United States
  • FIGI BBG000BNPSQ9
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
15.41
Price to sales ratio
3.86

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
518
ROIV
Roivant Sciences Ltd. - Common Shares
34.51 USD-4.06%-2.73%+14.80%+88.48%24.82 B USD
535
INSM
Insmed Incorporated - Common Stock
109.14 USD-5.60%-3.60%+10.53%-32.65%23.66 B USD
557
UTHR
United Therapeutics Corporation - Common Stock
535.57 USD-2.10%-4.20%-1.90%+79.90%22.73 B USD
573
BNTX
BioNTech SE - American Depositary Shares
90.07 USD-1.55%-4.60%-1.25%-18.86%21.61 B USD

Frequently asked questions about Incyte Corporation - Common Stock

What is the Incyte Corporation - Common Stock stock price today?

The current price of Incyte Corporation - Common Stock (INCY) is 114.23. Over the past 24 hours, the stock has changed by -2.12%. Follow the INCY chart for real-time price dynamics.

What is the stock ticker of Incyte Corporation - Common Stock?

Incyte Corporation - Common Stock trades under the ticker INCY. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Incyte Corporation - Common Stock stock going up?

INCY has changed by -2.81% over the last week, +5.79% over the last month, and +63.47% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Incyte Corporation - Common Stock net income for the last quarter?

Incyte Corporation - Common Stock reported net income of 303.33 M for the last quarter. The previous quarter showed 299.28 M, which means net income changed by +1.35%.

How many employees does Incyte Corporation - Common Stock have?

As of the latest available data, Incyte Corporation - Common Stock has 2 844 employees. Workforce size can provide additional context about the company's scale and operations.

What is Incyte Corporation - Common Stock EBITDA?

Incyte Corporation - Common Stock EBITDA is 324.92 M, and its EBITDA margin is 25.53%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Incyte Corporation - Common Stock stock?

You can buy Incyte Corporation - Common Stock (INCY) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Incyte Corporation - Common Stock stock?

Investing in Incyte Corporation - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the INCY chart and related analysis on metatrader.com as part of your research.

Incyte Corporation - Common Stock

Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.

News